US regulatory hurry-up brings Algeta's Alpharadin closer for prostate cancer
This article was originally published in Scrip
Executive Summary
The US FDA has granted fast-track designation to Algeta's Alpharadin (radium-223 chloride) for the treatment of castration-resistant (hormone refractory) prostate cancer patients with bone metastases.